Oxytocin, HCG Show Promise for Intractable Pain Despite the availability of shingles immunization and treatment options, the incidence of postherpetic neuralgia is increasing. Postherpetic neuralgia ...

LAS VEGAS—Postherpetic neuralgia (PHN) is often unrecognized and undertreated, and most patients have persistent pain despite treatment, said Charles E. Argoff, MD, CPE. For these reasons, care should ...

The overall incidence of PHN at 6 months was 9.8%, comparing favorably with historic controls for patients with zoster treated with antivirals alone (30%-40% incidence [8]); Gabapentin was well ...

Based on evidence from randomized trials, tricyclic antidepressants (TCAs) seem to be the only agents of proven benefit for established post-herpetic neuralgia (PHN). PHN occurs as a complication of ...

"Postherpetic Neuralgia Clinical Trials"DelveInsight's,“Postherpetic Neuralgia - Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Postherpetic ...

SAN MATEO, Calif., Oct. 22 /PRNewswire-FirstCall/ -- NeurogesX, Inc. , a biopharmaceutical company focused on developing and commercializing novel pain management ...

First and only prescription strength capsaicin product can provide up to 12 weeks of reduced pain from a single one-hour treatment SAN MATEO, Calif., Nov 16, 2009 /PRNewswire-FirstCall via COMTEX News ...

The FDA has approved gabapentin enacarbil extended-release tablets for the management of postherpetic neuralgia, a neuropathic pain syndrome that follows the healing of herpes zoster. The recommended ...

Despite its efficacy for the treatment of postherpetic neuralgia, the potential benefits from treatment with gabapentin may be somewhat limited by its intrinsic properties. Gabapentin’s absorption ...

LAVAL, Québec, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage ...

LAVAL, Quebec, July 27, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic (PK) ...